CHARM Therapeutics
CompanyUnited Kingdom
CHARM Therapeutics develops one asset, in phase 1 (CHM-029 in acute myeloid leukemia). Mostly small molecule acting on epigenetic regulation of gene expression and MEN1; based in the United Kingdom.
- 1
- Asset
- Furthest stage
- Phase 1
- 0
- Trials
- 0
- Signals
Pipeline
1Inhibits menin to overcome resistance in acute myeloid leukemia
Phase 1, Small molecule, Epigenetic regulation of gene expression, MEN1, acute myeloid leukemia
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Similar companies6